What is the recommended dose of Anoro Ellipta (umeclidinium/vilanterol) for Chronic Obstructive Pulmonary Disease (COPD) management?

Recommended Dose of Anoro Ellipta for COPD Management

The recommended dosage of Anoro Ellipta (umeclidinium/vilanterol) for maintenance treatment of COPD is one inhalation of 62.5 mcg umeclidinium and 25 mcg vilanterol once daily by oral inhalation. 1

Dosing Information

• Anoro Ellipta should be administered at the same time every day for optimal effect 1
• No dosage adjustment is required for elderly patients, patients with renal impairment, or patients with moderate hepatic impairment 1
• Do not use Anoro Ellipta more than once every 24 hours as this may increase the risk of adverse effects without providing additional therapeutic benefit 1

Clinical Evidence Supporting Once-Daily Dosing

• Umeclidinium/vilanterol 62.5/25 μg once daily (equivalent to a delivered dose of 55/22 μg) has demonstrated significant improvements in pulmonary function compared to placebo and individual components in clinical trials 2
• The once-daily dosing regimen provides the convenience of simplified administration, which may improve adherence in patients with COPD 2
• Clinical trials of up to 24 weeks' duration have confirmed the efficacy and safety of this dosing regimen 2

Formulation and Administration

• Anoro Ellipta is available as an inhalation powder containing 62.5 mcg umeclidinium and 25 mcg vilanterol per actuation 1
• The medication is administered using the Ellipta multi-dose dry powder inhaler, which has been shown to be easy to use for most patients 2
• Proper inhaler technique should be demonstrated to patients before prescribing, as up to 76% of COPD patients may make important errors when using their inhalers 3

Therapeutic Benefits at Recommended Dose

• At the recommended dose, Anoro Ellipta has been shown to improve:
  • Lung function (measured by FEV1) 2
  • Dyspnea (shortness of breath) 2
  • Reduced use of rescue medication 2
  • Health-related quality of life 2
  • Exercise endurance in some studies 2

Safety Considerations

• The most common adverse events reported with Anoro Ellipta at the recommended dose are headache and nasopharyngitis 2
• Pooled clinical trial data suggest that Anoro Ellipta is not associated with a clinically relevant increased risk of cardiovascular adverse events in COPD patients 2
• Anoro Ellipta is contraindicated in patients with severe hypersensitivity to milk proteins or demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the excipients 1

Important Limitations and Precautions

• Anoro Ellipta is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma 1
• The safety and effectiveness of Anoro Ellipta in asthma have not been established 1
• Anoro Ellipta should not be initiated during rapidly deteriorating or potentially life-threatening episodes of COPD 1
• Beta-blocking agents (including eyedrop formulations) should be avoided in patients using Anoro Ellipta 4

Clinical Comparisons

• Studies have shown that umeclidinium/vilanterol is significantly more effective than once-daily tiotropium bromide monotherapy and twice-daily fixed combination of salmeterol/fluticasone propionate at improving pulmonary function 2
• Single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) has been shown to be non-inferior to using two inhalers (FF/VI + UMEC) for COPD management 5

By following the recommended once-daily dosing of Anoro Ellipta (62.5 mcg umeclidinium/25 mcg vilanterol), patients with COPD can experience improved lung function and quality of life with a convenient dosing schedule that may enhance medication adherence.